Tarsus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Co.'s primary product candidate, TP-03, is an investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Co. is developing product candidates to address targeted diseases with unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease, TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. The TARS average annual return since 2020 is shown above.
The Average Annual Return on the TARS average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TARS average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TARS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|